- AdventHealth Research Institute
Accurately determining food intake remains a challenge in nutrition research. A new study published in Nature Metabolism, co-authored by AdventHealth Translational Research Institute (TRI) investigator Karen D. Corbin, PhD, RD, introduces a metagenomics-powered approach to accurately track dietary intake from gut microbiome samples.
Developed by Christian Diener, PhD, in the Gibbons Lab at the Institute for Systems Biology (ISB), the new method, called MEDI (Metagenomic Estimation of Dietary Intake), detects food-derived DNA in stool samples to estimate dietary intake, allowing for data-driven diet tracking without the use of questionnaires. Data from AdventHealth TRI’s Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance study (NCT02939703) published in Nature Communications in 2023 helped to validate this new method.
MEDI leverages stool metagenomics, a sequencing of all the DNA present in fecal samples, including microbial, human, and food-derived DNA. This non-invasive, data-driven approach offers an objective alternative to traditional food diaries and questionnaires, which are still the gold standard in dietary assessment but can suffer from misreporting and compliance issues.
Key findings of the latest study include the following:
- An Alternative to Questionnaire-Based Diet Tracking: Leveraging a database of more than 400 food items and over 300 billion base pairs of genomic information, MEDI accurately detected food intake patterns in infants and adults, and across two controlled feeding studies.
- Connecting Dietary Intake to Nutrition: MEDI converts the relative abundance profile of specific food items into nutrient profiles, assuming a 100-gram portion. These nutrient profiles show good agreement with data from controlled feeding studies, including AdventHealth’s microbiome study.
- Identified Diet-Related Health Risks: Without food logs, MEDI pinpointed dietary features linked to metabolic syndrome in a large clinical cohort.
“This is the perfect example of how collaboration advances science,” shares Dr. Corbin. “The data from our original TRI study was a small but important piece of this new research. We’re excited about the potential power this work holds to expand our overall understanding of interactions between diet and the gut microbiome and to further development of precision nutrition approaches that could help reduce obesity and other chronic diseases.”
Recent News
Clinical Trial Evidence on Diet and Type 1 Diabetes Outcomes
A new systematic review of clinical trials has found that no single dietary pattern consistently improves blood sugar control or weight management in youth and adults living with type 1 diabetes.
How Diet Shapes Gut Microbes and Energy Absorption
What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity.
AdventHealth Neuroscience Institute Launches NIH-Funded THRIVE Trial
AdventHealth Neuroscience Institute has launched THRIVE, an NIH-funded clinical trial led by Lauren Oberlin, PhD, geriatric neuropsychologist and neuroscience researcher.
AdventHealth Tampa Enrolls First Patient in the Tectonic CAD IVL Trial
On September 19, 2025, AdventHealth Tampa successfully enrolled its first patient in the Tectonic CAD Intravascular Lithotripsy (IVL) Trial, led by Dr. Mahmaljy and his team.
MANIFEST US Study Presented as a Late-Breaking Clinical Trial at AHA
The cardiovascular team is excited to highlight the MANIFEST US study, which was presented on November 10th as a Late-Breaking Clinical Trial at the American Heart Association (AHA) Scientific...
Nourishing Your Gut: Dr. Karen Corbin on the Power of Fiber
Dr. Karen Corbin, associate investigator at the AdventHealth Translational Research Institute for Metabolism and Diabetes in Orlando, emphasizes the essential role of diet in maintaining a healthy gut...
Southeast Region – Redmond Campus: AdventHealth Recognized as Top Enroller Nationally for the CARVTOP-ICD Trial
AdventHealth Research Institute (AHRI) is proud to announce that the Southeast Region’s Redmond Campus has been recognized as the top enrolling site nationally for the CARVTOP-ICD trial.
Stiff Arteries Linked to Early Memory Decline: New Findings by Dr. Amani Norling
Amani Norling, PhD a post-doctoral fellow at the AdventHealth Neuroscience institute, has published a notable paper titled “Arterial stiffness moderates the link between NfL and cognition: The IGNITE...
First BrioVAD Implant Successfully Completed
On September 24, the Transplant team successfully implanted the first BrioVAD device at AdventHealth, a major milestone in the ongoing INNOVATE 2254936 Vidic trial.
Advancing T1D Science: New TRI Publications
Researchers at the AdventHealth Translational Research Institute continue to drive meaningful progress in Type 1 diabetes—work that is being recognized not just in Central Florida, but throughout the...
The T1D Daily Reset: Small Habits With Big Impact
As we head into 2026, many people living with Type 1 diabetes are looking for ways to reset their routines and start the year feeling more balanced and in control.
The Next Frontier: Preventing Type 1 Diabetes Before It Starts
Recent research led by AdventHealth’s Translational Research Institute and others reveals that Type 1 diabetes develops gradually and can now be detected early through blood tests, opening the door to...